S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature

Aurora Cannabis (ACB) Competitors

$3.17
+0.03 (+0.96%)
(As of 03/1/2024 ET)

ACB vs. MNMD, MDWD, CDXC, FTLF, CGC, BTMD, GNLX, IVA, AUGX, and ALIM

Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Mind Medicine (MindMed) (MNMD), MediWound (MDWD), ChromaDex (CDXC), FitLife Brands (FTLF), Canopy Growth (CGC), biote (BTMD), Genelux (GNLX), Inventiva (IVA), Augmedix (AUGX), and Alimera Sciences (ALIM). These companies are all part of the "medical" sector.

Aurora Cannabis vs.

Mind Medicine (MindMed) (NASDAQ:MNMD) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.

Mind Medicine (MindMed) has higher earnings, but lower revenue than Aurora Cannabis. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mind Medicine (MindMed)N/AN/A-$56.80M-$2.45-2.54
Aurora Cannabis$174.88M0.99-$799.22M-$2.90-1.09

Mind Medicine (MindMed) has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500.

In the previous week, Mind Medicine (MindMed) had 11 more articles in the media than Aurora Cannabis. MarketBeat recorded 19 mentions for Mind Medicine (MindMed) and 8 mentions for Aurora Cannabis. Mind Medicine (MindMed)'s average media sentiment score of 0.78 beat Aurora Cannabis' score of -0.10 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mind Medicine (MindMed)
2 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aurora Cannabis
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mind Medicine (MindMed) has a net margin of 0.00% compared to Mind Medicine (MindMed)'s net margin of -48.82%. Mind Medicine (MindMed)'s return on equity of -23.27% beat Aurora Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed)N/A -89.72% -65.33%
Aurora Cannabis -48.82%-23.27%-15.75%

Aurora Cannabis received 350 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 88.57% of users gave Mind Medicine (MindMed) an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.

CompanyUnderperformOutperform
Mind Medicine (MindMed)Outperform Votes
31
88.57%
Underperform Votes
4
11.43%
Aurora CannabisOutperform Votes
381
59.44%
Underperform Votes
260
40.56%

Mind Medicine (MindMed) currently has a consensus price target of $24.83, indicating a potential upside of 298.61%. Given Aurora Cannabis' higher probable upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than Aurora Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed)
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aurora Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

9.7% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 11.2% of Aurora Cannabis shares are held by institutional investors. 2.1% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mind Medicine (MindMed) beats Aurora Cannabis on 9 of the 16 factors compared between the two stocks.


Get Aurora Cannabis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACB vs. The Competition

MetricAurora CannabisMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$172.89M$1.21B$5.20B$7.62B
Dividend YieldN/A4.45%2.82%3.87%
P/E Ratio-1.094.80212.6016.70
Price / Sales0.9915.623,035.5480.28
Price / CashN/A245.6899.4255.35
Price / Book0.422.394.534.54
Net Income-$799.22M-$177.55M$114.95M$211.55M
7 Day Performance-2.76%-2.09%5.70%3.36%
1 Month Performance-18.30%-3.32%11.24%6.68%
1 Year Performance-61.60%-16.07%14.08%8.85%

Aurora Cannabis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MNMD
Mind Medicine (MindMed)
1.3482 of 5 stars
$4.91
+2.9%
$23.50
+378.6%
+77.0%$196.89MN/A-2.6148Analyst Report
Analyst Revision
News Coverage
MDWD
MediWound
1.654 of 5 stars
$13.40
+1.1%
$32.00
+138.8%
+15.5%$123.36M$24.97M-7.6183
CDXC
ChromaDex
3.4949 of 5 stars
$1.52
flat
$5.80
+281.6%
-1.8%$114.19M$83.37M-16.89113Upcoming Earnings
FTLF
FitLife Brands
0 of 5 stars
$22.22
+0.1%
N/A+18.8%$98.88M$28.80M25.2527Short Interest ↑
Positive News
Gap Down
CGC
Canopy Growth
2.0243 of 5 stars
$3.36
-0.3%
$4.87
+44.8%
-85.7%$306.13M$304.79M-0.221,621Short Interest ↑
BTMD
biote
1.969 of 5 stars
$6.05
+10.2%
$7.71
+27.4%
+25.1%$440.20M$164.96M-27.50186Positive News
High Trading Volume
GNLX
Genelux
1.8805 of 5 stars
$6.67
-3.1%
$35.00
+424.7%
-57.0%$178.21M$238,000.000.0022Upcoming Earnings
Short Interest ↑
High Trading Volume
IVA
Inventiva
2.7244 of 5 stars
$3.42
+0.9%
$16.00
+367.8%
-22.2%$178.25M$12.83M0.00117Positive News
High Trading Volume
AUGX
Augmedix
1.4844 of 5 stars
$4.31
-1.8%
$6.00
+39.2%
N/A$178.26M$30.93M-8.451,040Short Interest ↓
News Coverage
Positive News
ALIM
Alimera Sciences
3.1549 of 5 stars
$3.37
+1.8%
$6.50
+92.9%
+90.3%$176.66M$54.13M-1.28150Short Interest ↓
News Coverage

Related Companies and Tools

This page (NASDAQ:ACB) was last updated on 3/2/2024 by MarketBeat.com Staff